$DTIL
PRECISION BIOSCIENCES INC

2024 Q4 Form 10-Q Financial Statement

#000095017024120279 Filed on November 04, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $576.0K
YoY Change -95.61%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.767M
YoY Change -8.96%
% of Gross Profit
Research & Development $13.08M
YoY Change -17.45%
% of Gross Profit
Depreciation & Amortization $715.0K
YoY Change -55.86%
% of Gross Profit
Operating Expenses $21.85M
YoY Change -14.25%
Operating Profit -$21.28M
YoY Change 72.09%
Interest Expense $256.0K
YoY Change -55.56%
% of Operating Profit
Other Income/Expense, Net $4.850M
YoY Change 1817.0%
Pretax Income -$16.43M
YoY Change 35.63%
Income Tax
% Of Pretax Income
Net Earnings -$16.43M
YoY Change 103.3%
Net Earnings / Revenue -2851.56%
Basic Earnings Per Share -$2.25
Diluted Earnings Per Share -$2.25
COMMON SHARES
Basic Shares Outstanding 7.671M 7.234M
Diluted Shares Outstanding 7.287M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $101.2M
YoY Change -17.18%
Cash & Equivalents $98.75M
Short-Term Investments $2.450M
Other Short-Term Assets $471.0K
YoY Change 34.96%
Inventory
Prepaid Expenses $7.114M
Receivables $188.0K
Other Receivables $0.00
Total Short-Term Assets $110.5M
YoY Change -24.22%
LONG-TERM ASSETS
Property, Plant & Equipment $3.563M
YoY Change -59.23%
Goodwill
YoY Change
Intangibles $388.0K
YoY Change -60.29%
Long-Term Investments $3.206M
YoY Change 78.11%
Other Assets $224.0K
YoY Change -4.27%
Total Long-Term Assets $42.74M
YoY Change 131.1%
TOTAL ASSETS
Total Short-Term Assets $110.5M
Total Long-Term Assets $42.74M
Total Assets $153.3M
YoY Change -6.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $958.0K
YoY Change 80.41%
Accrued Expenses $8.160M
YoY Change 20.0%
Deferred Revenue $175.0K
YoY Change -99.0%
Short-Term Debt $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.98M
YoY Change -76.33%
LONG-TERM LIABILITIES
Long-Term Debt $22.28M
YoY Change
Other Long-Term Liabilities $188.0K
YoY Change -75.46%
Total Long-Term Liabilities $188.0K
YoY Change -75.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.98M
Total Long-Term Liabilities $188.0K
Total Liabilities $88.39M
YoY Change -34.66%
SHAREHOLDERS EQUITY
Retained Earnings -$464.7M
YoY Change -1.82%
Common Stock $530.5M
YoY Change 5.4%
Preferred Stock
YoY Change
Treasury Stock (at cost) $952.0K
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity $64.87M
YoY Change
Total Liabilities & Shareholders Equity $153.3M
YoY Change -6.75%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$16.43M
YoY Change 103.3%
Depreciation, Depletion And Amortization $715.0K
YoY Change -55.86%
Cash From Operating Activities -$5.912M
YoY Change -74.4%
INVESTING ACTIVITIES
Capital Expenditures $64.00K
YoY Change -85.12%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$64.00K
YoY Change -100.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.733M
YoY Change -12543.33%
NET CHANGE
Cash From Operating Activities -5.912M
Cash From Investing Activities -64.00K
Cash From Financing Activities 3.733M
Net Change In Cash -2.243M
YoY Change -85.58%
FREE CASH FLOW
Cash From Operating Activities -$5.912M
Capital Expenditures $64.00K
Free Cash Flow -$5.976M
YoY Change -74.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001357874
dei Entity Registrant Name
EntityRegistrantName
PRECISION BIOSCIENCES INC
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://precisionbiosciences.com/20240930#InvestmentInIECUREMember
CY2023Q4 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://precisionbiosciences.com/20240930#InvestmentInIECUREMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38841
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4206017
dei Entity Address Address Line1
EntityAddressAddressLine1
302 East Pettigrew St.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite A-100
dei Entity Address City Or Town
EntityAddressCityOrTown
Durham
dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27701
dei City Area Code
CityAreaCode
919
dei Local Phone Number
LocalPhoneNumber
314-5512
dei Security12b Title
Security12bTitle
Common Stock, par value $0.000005 per share
dei Trading Symbol
TradingSymbol
DTIL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11982000
CY2024Q3 us-gaap Loans Payable
LoansPayable
22278000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
26582000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
73082000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6754000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7723000
CY2024Q3 dtil Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
10608000
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
10000000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
10000000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
188000
CY2023Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
128000
CY2024Q3 us-gaap Liabilities
Liabilities
88392000
CY2023Q4 us-gaap Liabilities
Liabilities
140920000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000005
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000005
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7507536
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7480521
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4191053
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4164038
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
530536000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
509443000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-464719000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-489631000
CY2024Q3 us-gaap Treasury Stock Value
TreasuryStockValue
952000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
64866000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
18861000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
153258000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
159781000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
576000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13120000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68058000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41689000
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7671059
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98752000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116678000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
188000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
901000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2450000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7114000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5977000
CY2023Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
11897000
CY2024Q3 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
189000
CY2023Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
487000
CY2024Q3 dtil Contract Asset Current
ContractAssetCurrent
1359000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
471000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
419000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
110523000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
136359000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
22576000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3563000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6338000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
388000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
400000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7393000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8263000
CY2024Q3 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
3206000
CY2023Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
3206000
CY2024Q3 us-gaap Notes Receivable Net
NotesReceivableNet
5385000
CY2023Q4 us-gaap Notes Receivable Net
NotesReceivableNet
4990000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
224000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
225000
CY2024Q3 us-gaap Assets
Assets
153258000
CY2023Q4 us-gaap Assets
Assets
159781000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
958000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2968000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3592000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4978000
CY2024Q3 dtil Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3293000
CY2023Q4 dtil Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1557000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
175000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
12035000
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
22412000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1275000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1133000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1385000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2391000
CY2024Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1304000
CY2023Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
2513000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11982000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
49987000
CY2024Q3 us-gaap Loans Payable
LoansPayable
22278000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
26582000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
73082000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6754000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7723000
CY2024Q3 dtil Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
10608000
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
10000000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
10000000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
188000
CY2023Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
128000
CY2024Q3 us-gaap Liabilities
Liabilities
88392000
CY2023Q4 us-gaap Liabilities
Liabilities
140920000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000005
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
530536000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
509443000
CY2024Q3 us-gaap Treasury Stock Value
TreasuryStockValue
952000
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
952000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
64866000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
18861000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
576000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13120000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68058000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41689000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13084000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15850000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43652000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39986000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8767000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9633000
us-gaap Operating Expenses
OperatingExpenses
70535000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21275000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13084000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15850000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43652000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39986000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8767000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9633000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25722000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30549000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
21851000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
25483000
us-gaap Operating Expenses
OperatingExpenses
69374000
us-gaap Operating Expenses
OperatingExpenses
70535000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21275000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12363000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1316000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28846000
CY2024Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-875000
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1350000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-112000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-4060000
CY2024Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
571000
CY2023Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
311000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
917000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-458000
CY2024Q3 dtil Gain On Change In Fair Value Of Warrant Liability
GainOnChangeInFairValueOfWarrantLiability
3647000
us-gaap Interest Expense
InterestExpense
1390000
us-gaap Interest Expense
InterestExpense
1651000
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
1763000
us-gaap Interest Income Other
InterestIncomeOther
5269000
us-gaap Interest Income Other
InterestIncomeOther
5859000
CY2023Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-254000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
63000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4850000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
26228000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-247000
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-16425000
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-12110000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
24912000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-29093000
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
4031000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-15937000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16425000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8079000
us-gaap Net Income Loss
NetIncomeLoss
24912000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.87
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12363000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1316000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28846000
CY2024Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-875000
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1350000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-112000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-4060000
CY2024Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
571000
CY2023Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
311000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
917000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-458000
CY2024Q3 dtil Gain On Change In Fair Value Of Warrant Liability
GainOnChangeInFairValueOfWarrantLiability
3647000
dtil Gain On Change In Fair Value Of Warrant Liability
GainOnChangeInFairValueOfWarrantLiability
21798000
CY2024Q3 us-gaap Interest Expense
InterestExpense
256000
CY2023Q3 us-gaap Interest Expense
InterestExpense
576000
us-gaap Interest Expense
InterestExpense
1390000
us-gaap Interest Expense
InterestExpense
1651000
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
1763000
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
1870000
us-gaap Interest Income Other
InterestIncomeOther
5269000
us-gaap Interest Income Other
InterestIncomeOther
5859000
CY2023Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-254000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
63000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4850000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
253000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
26228000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-247000
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-16425000
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-12110000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
24912000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-29093000
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
4031000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-15937000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16425000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8079000
us-gaap Net Income Loss
NetIncomeLoss
24912000
us-gaap Net Income Loss
NetIncomeLoss
-45030000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.9
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.1
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.9
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7287173
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.1
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7287173
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3838900
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6441375
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3784432
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7287173
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3838900
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6590885
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
266000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4092000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
416000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-25060000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
40177000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3874000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1881000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11891000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
34041000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3105000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
104000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-108000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8079000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
29063000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
18861000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
112000
CY2024Q1 dtil Stock Issued During Period Value Collaboration Partners And Licenses
StockIssuedDuringPeriodValueCollaborationPartnersAndLicenses
905000
CY2024Q1 dtil Stock And Warrants Issued During Period Value Through Underwritten Offering Net Of Issuance Cost
StockAndWarrantsIssuedDuringPeriodValueThroughUnderwrittenOfferingNetOfIssuanceCost
4610000
CY2024Q1 dtil Stock Issued During Period Value Through Atm Facility Net Of Issuance Cost
StockIssuedDuringPeriodValueThroughATMFacilityNetOfIssuanceCost
1224000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
8588000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
37206000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2928000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
300000
CY2024Q2 dtil Stock Issued During Period Value Through Atm Facility Net Of Issuance Cost
StockIssuedDuringPeriodValueThroughATMFacilityNetOfIssuanceCost
1531000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
32749000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
74714000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3199000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
137000
CY2024Q3 dtil Stock Issued During Period Value Through Atm Facility Net Of Issuance Cost
StockIssuedDuringPeriodValueThroughATMFacilityNetOfIssuanceCost
3241000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16425000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
64866000
us-gaap Profit Loss
ProfitLoss
24912000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2950000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5538000
us-gaap Share Based Compensation
ShareBasedCompensation
9033000
us-gaap Share Based Compensation
ShareBasedCompensation
11071000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-254000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3838900
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6441375
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3784432
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3838900
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6590885
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3784432
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
60433000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
266000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4092000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
416000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-25060000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
40177000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3874000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1881000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11891000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
34041000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3105000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
104000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-108000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8079000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
29063000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
18861000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
112000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2906000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
8588000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
37206000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2928000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
300000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
32749000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
74714000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
137000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16425000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
64866000
us-gaap Profit Loss
ProfitLoss
24912000
us-gaap Profit Loss
ProfitLoss
-45030000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2950000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5538000
us-gaap Share Based Compensation
ShareBasedCompensation
9033000
us-gaap Share Based Compensation
ShareBasedCompensation
11071000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-254000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
63000
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
8446000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
228000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
315000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
870000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1161000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
63000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
228000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
315000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
870000
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-458000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-112000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-4060000
dtil Amortization Of Discount On Note Receivable
AmortizationOfDiscountOnNoteReceivable
506000
dtil Amortization Of Discount On Note Receivable
AmortizationOfDiscountOnNoteReceivable
313000
dtil Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
21798000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1137000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1047000
us-gaap Increase Decrease In Marketable Securities Restricted
IncreaseDecreaseInMarketableSecuritiesRestricted
-607000
us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
-9750000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-713000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2773000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
1359000
dtil Increase Decrease In Other Assets And Other Current Assets
IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets
147000
dtil Increase Decrease In Other Assets And Other Current Assets
IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets
-1539000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2168000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-495000
dtil Increase Decrease In Accrued Other Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities
-1972000
dtil Increase Decrease In Accrued Other Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities
-3101000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-58360000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-37721000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-827000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-844000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39762000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-75691000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
8000000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
153000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1983000
dtil Payments To Purchase Intangible Assets
PaymentsToPurchaseIntangibleAssets
25000
dtil Payments To Purchase Intangible Assets
PaymentsToPurchaseIntangibleAssets
300000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
60000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
70000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-118000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5787000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000
dtil Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
249000
dtil Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
370000
dtil Proceeds From Offering Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts
43393000
dtil Proceeds From Offering Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts
2159000
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
905000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
22505000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
22488000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44530000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2559000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4650000
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
917000
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-458000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-112000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-4060000
dtil Amortization Of Discount On Note Receivable
AmortizationOfDiscountOnNoteReceivable
506000
dtil Amortization Of Discount On Note Receivable
AmortizationOfDiscountOnNoteReceivable
313000
dtil Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
21798000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1137000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1047000
us-gaap Increase Decrease In Marketable Securities Restricted
IncreaseDecreaseInMarketableSecuritiesRestricted
-607000
us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
-9750000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-713000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2773000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
1359000
dtil Increase Decrease In Other Assets And Other Current Assets
IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets
147000
dtil Increase Decrease In Other Assets And Other Current Assets
IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets
-1539000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2168000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-495000
dtil Increase Decrease In Accrued Other Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities
-1972000
dtil Increase Decrease In Accrued Other Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities
-3101000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-58360000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-37721000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-827000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-844000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39762000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-75691000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
8000000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
153000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1983000
dtil Payments To Purchase Intangible Assets
PaymentsToPurchaseIntangibleAssets
25000
dtil Payments To Purchase Intangible Assets
PaymentsToPurchaseIntangibleAssets
300000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
60000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
70000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-118000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5787000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000
dtil Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
249000
dtil Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
370000
dtil Proceeds From Offering Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts
43393000
dtil Proceeds From Offering Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts
2159000
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
905000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
22505000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
22488000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44530000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2559000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4650000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-67345000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
116678000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
0
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
58000000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
22600000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-67345000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122231000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98752000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122231000
us-gaap Interest Paid Net
InterestPaidNet
1366000
us-gaap Interest Paid Net
InterestPaidNet
1491000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Business</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Precision BioSciences, Inc. (the “Company”) was incorporated on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 26, 2006</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> under the laws of the State of Delaware and is based in Durham, North Carolina. The Company is a gene editing company dedicated to improving life by developing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">therapies for genetic and infectious diseases with the application of the Company’s wholly-owned proprietary ARCUS genome editing platform.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its inception, the Company has devoted substantially all of its efforts to research and development activities, recruiting skilled personnel, establishing its intellectual property portfolio and providing general and administrative support for these operations. The Company is subject to a number of risks similar to those of other companies conducting early-stage research and development of product candidates. Principal among these risks are the Company's dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its product candidates. The Company’s success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, obtain regulatory approval of its products, successfully commercialize its products, generate revenue, meet its obligations, and, ultimately, attain profitable operations.</span></p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-01-26
us-gaap Comparability Of Prior Year Financial Data
ComparabilityOfPriorYearFinancialData
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Interim Financial Information</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited condensed financial statements and notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in the annual financial statements, prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”), have been condensed or omitted pursuant to those rules and regulations. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 27, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The unaudited condensed financial statements have been prepared on the same basis as the audited financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair presentation of the Company’s condensed financial position as of September 30, 2024 and condensed results of operations for the three and nine months ended September 30, 2024 and 2023 and the condensed cash flows for the nine months ended September 30, 2024 and 2023, have been made. The Company’s condensed results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
30
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
189576000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121328000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122231000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
22576000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121328000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122231000
dtil Fair Value Of Convertible Note From Disposal Of Business
FairValueOfConvertibleNoteFromDisposalOfBusiness
11366000
us-gaap Interest Paid Net
InterestPaidNet
1366000
us-gaap Interest Paid Net
InterestPaidNet
1491000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Business</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Precision BioSciences, Inc. (the “Company”) was incorporated on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 26, 2006</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> under the laws of the State of Delaware and is based in Durham, North Carolina. The Company is a gene editing company dedicated to improving life by developing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">therapies for genetic and infectious diseases with the application of the Company’s wholly-owned proprietary ARCUS genome editing platform.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its inception, the Company has devoted substantially all of its efforts to research and development activities, recruiting skilled personnel, establishing its intellectual property portfolio and providing general and administrative support for these operations. The Company is subject to a number of risks similar to those of other companies conducting early-stage research and development of product candidates. Principal among these risks are the Company's dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its product candidates. The Company’s success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, obtain regulatory approval of its products, successfully commercialize its products, generate revenue, meet its obligations, and, ultimately, attain profitable operations.</span></p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-01-26
us-gaap Comparability Of Prior Year Financial Data
ComparabilityOfPriorYearFinancialData
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Interim Financial Information</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited condensed financial statements and notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in the annual financial statements, prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”), have been condensed or omitted pursuant to those rules and regulations. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 27, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The unaudited condensed financial statements have been prepared on the same basis as the audited financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair presentation of the Company’s condensed financial position as of September 30, 2024 and condensed results of operations for the three and nine months ended September 30, 2024 and 2023 and the condensed cash flows for the nine months ended September 30, 2024 and 2023, have been made. The Company’s condensed results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
30
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
3206000
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
3206000
CY2024Q3 dtil Assessed Fair Value Of Ordinary Shares
AssessedFairValueOfOrdinaryShares
2500000
dtil Gain On Convertible Note And Ordinary Shares
GainOnConvertibleNoteAndOrdinaryShares
900000
us-gaap Operating Lease Cost
OperatingLeaseCost
1458000
us-gaap Operating Lease Cost
OperatingLeaseCost
1410000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
568000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
555000
us-gaap Variable Lease Cost
VariableLeaseCost
316000
us-gaap Variable Lease Cost
VariableLeaseCost
610000
us-gaap Sublease Income
SubleaseIncome
320000
us-gaap Sublease Income
SubleaseIncome
45000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
0
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
58000000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
22600000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
0
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
3206000
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
3206000
CY2024Q3 dtil Assessed Fair Value Of Ordinary Shares
AssessedFairValueOfOrdinaryShares
2500000
dtil Gain On Convertible Note And Ordinary Shares
GainOnConvertibleNoteAndOrdinaryShares
900000
us-gaap Operating Lease Cost
OperatingLeaseCost
1458000
us-gaap Operating Lease Cost
OperatingLeaseCost
1410000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
568000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
555000
us-gaap Variable Lease Cost
VariableLeaseCost
316000
us-gaap Variable Lease Cost
VariableLeaseCost
610000
us-gaap Sublease Income
SubleaseIncome
320000
us-gaap Sublease Income
SubleaseIncome
45000
us-gaap Lease Cost
LeaseCost
2022000
us-gaap Lease Cost
LeaseCost
2530000
us-gaap Operating Lease Payments
OperatingLeasePayments
1403000
us-gaap Operating Lease Payments
OperatingLeasePayments
1799000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2491000
dtil Operating Lease Liabilities Arising From Obtaining Right Of Use Assets
OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
-1864000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M18D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.092
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
484000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1962000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2019000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2078000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2140000
CY2024Q3 dtil Lessee Operating Lease Liability Payments Due In Five Years And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueInFiveYearsAndThereafter
1269000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9952000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1923000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8029000
CY2024Q3 dtil Contingent Liability For Aggregate Minimum Lease Payments
ContingentLiabilityForAggregateMinimumLeasePayments
4700000
us-gaap Lease Cost
LeaseCost
2022000
us-gaap Lease Cost
LeaseCost
2530000
us-gaap Operating Lease Payments
OperatingLeasePayments
1403000
us-gaap Operating Lease Payments
OperatingLeasePayments
1799000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2491000
dtil Operating Lease Liabilities Arising From Obtaining Right Of Use Assets
OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
-1864000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M18D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.092
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
484000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1962000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2019000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2078000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2140000
CY2024Q3 dtil Lessee Operating Lease Liability Payments Due In Five Years And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueInFiveYearsAndThereafter
1269000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9952000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1923000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8029000
CY2024Q3 dtil Contingent Liability For Aggregate Minimum Lease Payments
ContingentLiabilityForAggregateMinimumLeasePayments
4700000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3199000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3105000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9033000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11071000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8769
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8793
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0344
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0367
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M24D
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3199000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3105000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9033000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11071000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8769
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8793
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0344
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0367
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M17D
CY2024Q3 dtil Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Fair Value Per Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption
7.55
dtil Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Fair Value Per Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption
7.76
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
349662
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
172.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
85034
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
23427
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
229.09
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
411269
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M17D
CY2024Q3 dtil Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Fair Value Per Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption
7.55
dtil Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Fair Value Per Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption
7.76
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
349662
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
172.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
85034
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
23427
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
229.09
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
411269
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
135.48
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
16700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
135.48
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
16700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2024Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-16425000
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-12110000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
24912000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-29093000
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
4031000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-15937000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16425000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8079000
us-gaap Net Income Loss
NetIncomeLoss
24912000
us-gaap Net Income Loss
NetIncomeLoss
-45030000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3838900
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6441375
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3784432
CY2024Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-16425000
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-12110000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
24912000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-29093000
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
4031000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-15937000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16425000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8079000
us-gaap Net Income Loss
NetIncomeLoss
24912000
us-gaap Net Income Loss
NetIncomeLoss
-45030000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7287173
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3838900
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6441375
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3784432
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
149510
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7287173
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3838900
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6590885
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3784432
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.25
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-3.15
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
3.87
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-7.69
CY2023Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
1.05
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
-4.21
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.9
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.25
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-3.15
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
3.78
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-4.21
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.1
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.9
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
149510
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7287173
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3784432
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.25
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-3.15
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
3.87
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-7.69
CY2023Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
1.05
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
-4.21
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.9
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.25
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-3.15
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
3.78
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-7.69
CY2023Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
1.05
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-4.21
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.1
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.9
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3012363
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
dtil Warrant Description
WarrantDescription
The warrants issued in the March 2024 Public Offering are classified as a liability in accordance with ASC 815, since these warrants met the definition of a derivative instrument and did not qualify for equity classification. These warrant agreements include a fundamental transaction clause whereby, in the event that another person or entity becomes the beneficial owner of 50% of the outstanding shares of the Company’s common stock, and if other conditions are met, the Company may be required to purchase the warrants from the holders by paying cash in an amount equal to the Black-Scholes value of the remaining unexercised portion of the warrants on the date of such fundamental transaction. This liability is subject to remeasurement at each balance sheet date until the warrants are exercised or expire, and any change in fair value is recognized in the Company’s condensed statements of operations.
CY2024Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
32400000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3012363
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
dtil Warrant Description
WarrantDescription
The warrants issued in the March 2024 Public Offering are classified as a liability in accordance with ASC 815, since these warrants met the definition of a derivative instrument and did not qualify for equity classification. These warrant agreements include a fundamental transaction clause whereby, in the event that another person or entity becomes the beneficial owner of 50% of the outstanding shares of the Company’s common stock, and if other conditions are met, the Company may be required to purchase the warrants from the holders by paying cash in an amount equal to the Black-Scholes value of the remaining unexercised portion of the warrants on the date of such fundamental transaction. This liability is subject to remeasurement at each balance sheet date until the warrants are exercised or expire, and any change in fair value is recognized in the Company’s condensed statements of operations.
CY2024Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
32400000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3600000
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2500000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2024Q1 dtil Warrants And Rights Issued
WarrantsAndRightsIssued
32406000
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
10386000
CY2024Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
22020000
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7764000
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
14256000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3648000
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
10608000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3600000
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2500000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2024Q1 dtil Warrants And Rights Issued
WarrantsAndRightsIssued
32406000
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
10386000
CY2024Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
22020000
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7764000
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
14256000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3648000
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
10608000
CY2024Q3 ecd Trd Arr Adoption Date
TrdArrAdoptionDate
September 10, 2024
CY2024Q3 ecd Trd Arr Ind Name
TrdArrIndName
Dario Scimeca
CY2024Q3 ecd Trd Arr Ind Title
TrdArrIndTitle
General Counsel
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
true
CY2024Q3 ecd Trd Arr Securities Agg Avail Amt
TrdArrSecuritiesAggAvailAmt
2821
CY2024Q3 ecd Trd Arr Adoption Date
TrdArrAdoptionDate
September 10, 2024
CY2024Q3 ecd Trd Arr Ind Name
TrdArrIndName
Dario Scimeca
CY2024Q3 ecd Trd Arr Ind Title
TrdArrIndTitle
General Counsel
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
true
CY2024Q3 ecd Trd Arr Securities Agg Avail Amt
TrdArrSecuritiesAggAvailAmt
2821

Files In Submission

Name View Source Status
0000950170-24-120279-index-headers.html Edgar Link pending
0000950170-24-120279-index.html Edgar Link pending
0000950170-24-120279.txt Edgar Link pending
0000950170-24-120279-xbrl.zip Edgar Link pending
dtil-20240930.htm Edgar Link pending
dtil-20240930.xsd Edgar Link pending
dtil-ex10_1.htm Edgar Link pending
dtil-ex10_5.htm Edgar Link pending
dtil-ex10_7.htm Edgar Link pending
dtil-ex31_1.htm Edgar Link pending
dtil-ex31_2.htm Edgar Link pending
dtil-ex32_1.htm Edgar Link pending
dtil-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
dtil-20240930_htm.xml Edgar Link completed